title: [Second look operation from the current viewpoint].
abstract: Tumor reduction or elimination during primary surgery is the most important goal to aim at. Platinum-containing poly-chemotherapies led to an increase in remissions. However, highly advanced technologies (computed tomography, ultrasonography, nuclear magnetic resonance) and combined analysis of tumor markers are not sensitive enough to evaluate tumor-free status. A false-positive rate up to 33% at the time of second-look surgery was assessed in patients in clinical complete remission. Therapeutic second-look surgery with the purpose of tumor reduction is not capable to prolong the patient's survival time. Therefore, second-look surgery is limited to a diagnostic procedure, resulting in an objective assessment of newly developed therapy strategies.
authors.affiliation: II. Universitäts-Frauenklinik, Wien, Osterreich.
authors.forename: H
authors.initials: H
authors.lastname: Janisch
mesh_terms: D003131:Combined Modality Therapy; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D010051:Ovarian Neoplasms / Q000401:mortality / Q000601:surgery*; D011183:Postoperative Complications / Q000401:mortality / Q000601:surgery*; D012086:Reoperation; D015996:Survival Rate
vernacular_title: Die "Second-look"-Operation aus heutiger Sicht.